Physician profile
Hailey Gase
NPI 1669193975
$1,146.21
in general payments reported to CMS, 2019-2025
16 companies · $84.55 in 2025
The $84.55 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $904 · 2024: $158 · 2025: $84.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $194.58 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $153.88 | 2023-2025 | Rexulti, Abilify Mycite |
| Idorsia Pharmaceuticals US INC | $142.54 | 2023 | Quviviq |
| Corium, LLC | $105.18 | 2023 | Azstarys, Azstarys |
| Tris Pharma INC | $96.41 | 2023-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $83.97 | 2024-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $74.18 | 2023 | Spravato, Invega Sustenna |
| Lundbeck LLC | $73.68 | 2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $43.74 | 2023 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $42.77 | 2023 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.29 | 2023 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $27.72 | 2024 | Uzedy |
| Neurocrine Biosciences, INC. | $25.77 | 2024 | Ingrezza |
| Neos Therapeutics, LP | $17.07 | 2024 | Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $14.40 | 2023 | Xelstrym |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.03 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Gase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.